

MAR 30 2001

510 (k) SUMMARY  
AS REQUIRED BY SECTION 807.92(C)

K003234

**Identification:** InstaCheck® Drug Screen Amphetamine 300 Test

**Description:** One-step, colloidal gold based chromatographic immunoassay for the rapid, qualitative detection of Amphetamine in urine.

**Name of Manufacturer:** Forefront Diagnostics, Inc.  
23561 Ridge Route Dr. Suite D  
Laguna Hills, CA 92653

**Intended Use:** The Forefront Diagnostics InstaCheck® Drug Screen Amphetamine 300 Test is an *in vitro* screen test for the rapid detection of Amphetamine in urine. The cut-off concentration is 300 ng/ml. The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons.

**Technology:** The InstaCheck® Drug Screen Amphetamine 300 Test, like currently marketed Drug Screen Single Tests from other manufacturers such as Roche, American Biotech Inc, etc, qualitatively measure the presence of target drugs or their metabolites by visual color sandwich one step immunoassay technology. All of these products are based on the same immunochemical principle of recognition and formation of specific antibody / target drug / antibody / complexes.

**Performance:** The product performance characteristics of InstaCheck® Drug Screen Amphetamine 300 Test was evaluated in a blind-labeled control study and in a blind-labeled clinical specimen correlation study. Correlation studies, using clinical specimens, produced >91% correlation when compared to GC/MS methodology. Clinical site studies, performed at Forefront Diagnostics, Inc and two independent laboratories, were also performed.

**Conclusion:** For the reasons mentioned above, it may be concluded that the InstaCheck® Drug Screen Amphetamine 300 Test can be performed by professional and laboratory personnel to obtain a visual, qualitative, rapid detection of Amphetamine.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAR 30 2001

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Ms. Feng-Yu Lee  
Vice President of Quality System  
Forefront Diagnostics, Inc.  
23561 Ridge Route Drive  
Suite D  
Laguna Hills, CA 92653

Re: K003234  
Trade Name: InstaCheck® Drug Screen Amphetamine 300 Test  
Regulatory Class: II  
Product Code: DKZ  
Dated: February 23, 2001  
Received: February 26, 2001

Dear Ms. Lee:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):

K003234

Device Name:

InstaCheck<sup>®</sup> Drug Screen Amphetamine 300 Test

Indications For Use:

**The Forefront Diagnostics InstaCheck<sup>®</sup> Drug Screen Amphetamine 300 Test is an in vitro screen test for the rapid detection of Amphetamine in human urine at a cutoff of 300 ng/ml. This test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons.**



(Division Signature)

Division of Clinical Laboratory Devices

510(k) Number

K003234

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)Prescription Use ☒  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_

(Optional Format 1-2-96)